

Preface

Timely Knowledge and Clinical Insights on Cancer and Rheumatic Disease



John Manley Davis III, MD, MS
Editor

Questions pertaining to cancer and rheumatic disease arise commonly in clinical practice. Clinicians commonly experience concern for the possibility that an atypical or undifferentiated inflammatory syndrome could be caused by an occult malignancy. Conversely, patients often raise justifiable concerns about the possibility a drug for their rheumatic disease may increase their lifetime risk of cancer. Estimates of the risk of cancer for a given rheumatic disease or related to a certain antirheumatic medication seem to vary from study to study. All parties to the care of patients with rheumatic diseases crave greater clarity on best practices for treatment and management. In this thematic issue on Cancer and Rheumatic Disease, experts in their fields provide their knowledge and clinical insights to address gaps in clinical practice and research. I am especially proud that all authors have taken a pragmatic and clinical approach by providing useful guidance on how to individualize patient assessment, with useful points on cancer screening as well as shared decision making about management. I am hopeful that the knowledge conveyed in this issue will provide an impetus for further clinical and translational studies on the interface between cancer and rheumatic diseases, which can be expected to provide new treatment options for people living with these conditions in the future. It has certainly been an honor and a privilege to work with my outstanding colleagues and with Elsevier to produce this thematic issue, and I am sincerely thankful to all for their great efforts. I hope

the readership of *Rheumatic Disease Clinics* finds the content of this issue valuable and useful in both the clinical and research settings.

John Manley Davis III, MD, MS
Mayo Clinic Rochester
200 1st Street Southwest
Rochester, MN 55905, USA

E-mail address:
davis.john4@mayo.edu